Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

12 Issues per year

40% increased IMPACT FACTOR 2012: 3.009
Rank 5 out of 31 in category Medical Laboratory Technology in the 2012 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

SELDI-TOF-MS proteomics of breast cancer

Charlotte H. Clarke1 / Julie A. Buckley2 / Eric T. Fung3

1.

2.

3.

Corresponding author: Eric T. Fung, Ciphergen Biosystems, Inc., Diagnostics Division, 6611 Dumbarton Circle, Fremont, CA 94555, USA Phone: +1-510-505-2242, Fax: +1-510-505-2101,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 43, Issue 12, Pages 1314–1320, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2005.225, November 2005

Publication History:
Received:
June 29, 2005
Accepted:
October 10, 2005
Published Online:
2005-11-28

Abstract

The detection, diagnosis, and management of breast cancer rely on an integrated approach using clinical history, physical examination, imaging, and histopathology. The discovery and validation of novel biomarkers will aid the physician in more effectively achieving this integration. This review discusses efforts in surface-enhanced laser desorption/ionization (SELDI)-based proteomics to address various clinical questions surrounding breast cancer, including diagnosis, monitoring, and stratification for treatment. Emphasis is placed on examining how study design and execution influence the discovery and validation process, which is critical to the proper development of potential clinical tests.

Keywords: biomarkers; breast cancer; diagnostics; proteomics; surface enhanced laser desorption/ionization (SELDI)

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.